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Abstract
Background: Determining the extent of seropositivity of SARS-CoV-2 antibody has the potential to guide
prevention and control efforts. We aimed to determine the seroprevalence of SARS-CoV-2 antibody among
individuals aged above15 years and residing in the congregate settings of Dire Dawa city administration, Ethiopia.
Method: We analyzed COVID-19 seroprevalence data on 684 individuals from a community based cross-sectional
survey conducted among individuals aged above 15 years and residing in congregate settings in Dire Dawa from
June 15 to July 30, 2020. Data were collected using interview and blood sample collection. Participants were asked
about demographic characteristics, COVID-19 symptoms, and their practice of preventive measures. Seroprevalence
was determined using SARS-CoV-2 IgG test. Bivariate and multivariate multilevel mixed effects logistic regression
model was fitted and statistical significance was set at p value < 0.05.
Result: The estimated SARS-CoV-2 seroprevalence was 3.2% (95 % CI 2.0–4.8) in the study region with no
differences by age and sex but considerable differences were observed by self-reported practice of COVID-19
preventive measures. The cluster effect is not significant (P = 0.396) which has suggested no evidence of
heterogeneity in SARS-CoV-2 seroprevalence among the clusters. The odds of SARS-CoV-2 antibody seroprevalence
were higher for individuals who were employed and work by moving from home to work area (AOR; 9.73 95% CI
2.51, 37.68), reported of not wearing facemasks when leaving home (AOR; 6.4 95% CI 2.30, 17.66) and did not
practice physical distancing measures (AOR; 10 95% CI 3.01, 33.20) compared to their counterparts, respectively. Our
estimated seroprevalence of SARS-CoV-2 among participants who reported not to have practiced social distancing
measures was 12.8 (95% CI, 7.0, 19) and 1.5 (95% CI, 0.5, 2.5) among those who reported of practicing them. More
than 80% of study participants reported of implementing infection prevention measures (face masks and physical
distancing recommendations).
Conclusion: The detected SARS-CoV-2 seroprevalence among the study participants was low at the time of the
survey indicating higher proportion of population yet to be infected. COVID-19 preventive measures were
associated with reduced seroprevalence and should be promoted to avoid transmission to the uninfected majority.
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Introduction
Coronavirus disease 2019 (COVID-19) emerged from
Wuhan, China, in December 2019 as a novel respiratory
illness caused by severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2). Subsequently, it was declared
as a pandemic that is a threat for every country in mid-
March 2020 by the World Health Organization (WHO)
[1]. Since then, the disease has claimed millions of lives
and has affected the economy and health throughout the
world. The spectrum of SARS-CoV-2 severity varies
broadly, from asymptomatic infection to severe compli-
cation like organ failure and death [2, 3].
Ethiopia reported the first case in March 2020 and
subsequently identified the epicenter at the national cap-
ital Addis Ababa; meanwhile, clusters were also detected
in the regional capitals including Dire Dawa. As of
March 06/2021, there were over 165,000 cases and more
than 2000 deaths from COVID-19 in Ethiopia [4].
Although, there was a single serosurvey among asymp-
tomatic people recruited from a clinical laboratory in May
2020 in Addis Ababa, Ethiopia, using only 99 people
tested [5], the actual population seroprevalence of disease,
and infection have not been measured. Therefore, com-
prehensive population level studies are required [6–8].
Population level COVID-19 seroprevalence can
allow inferences to be made about the extent of infec-
tion [9–12]. These findings can have the potential to
guide local preventive or control measures [13–16].
Population level seroprevalence studies also provide
the magnitude of population who have not yet been
infected; a vital information to plan for future trans-
mission control measures and health-care needs.
Therefore, this survey was designed to measure the
seroprevalence of SARS-CoV-2 antibody among indi-
viduals aged above 15 years and residing in congregate
settings in Dire Dawa city administration, Ethiopia,
which is adjacent to Somali Region that shares a
border with Djibouti; where there is high population
movement and high-risk social interactions. Data from
this survey will serve as a benchmark to show changes
in transmission rates in the studied population across
time.
Methods
Design, setting, and population
This study was part of the nationwide SARS-CoV-2 ser-
osurvey conducted in Ethiopia from mid-June to end of
July 2020. The national seroprevalence survey collected
data from participants above the age of 15 from all 11
administrative regions of Ethiopia. The sample size of
750 was calculated assuming 7.5% seroprevalence and
margin of error of 0.02 at 95% confidence interval. As
per the national quota of 16% of households to be
included into the survey, 300 households have been
included into the survey using systematic random sam-
pling. Nationally allocated quota of 750 sample size was
proportionally distributed to these enumeration sites de-
pending on the total number of households available at
each enumeration site. We obtained 684 complete sam-
ples for Dire Dawa city administration from the Ethiop-
ian Public Health Institute (EPHI). This scale of samples
meant that the study can sufficiently reflect the burden
at the time of the study. Individuals who resided in
households of the selected enumeration areas were in-
cluded into the study. Individuals with prior history of
RT-PCR test or being positive for RT-PCR test were ex-
cluded from the study due to the background character-
istics of the study participants that might affect the level
of participation into the study; which in turn might
introduce selection bias.
Dire Dawa is located 515 km from the national capital,
Addis Ababa to the east. The current total population of
Dire Dawa administration is 507, 000 (323, 000 for Dire
Dawa city administration) based on the population
projection by the Ethiopian Central Statistical Agency
[17]. Dire Dawa administration regional health bureau
was among the other sectors to engage early into the
establishment of emergency operation centers and task
forces following the first documented COVID 19 case in
Addis Ababa on March 13, 2020.
SARS-CoV-2 serosurvey was conducted among
individuals aged above 15 years and residing in randomly
selected households from purposively selected 11 enu-
meration areas in overcrowded neighborhoods. Over-
crowded neighborhoods used in this survey constituted
settings with residential houses from 1330 to 8050
within 1 km2 area as defined by the Ethiopian Central
Statistical Agency. At the time of survey, schools were
closed, and social gatherings including religious congre-
gations were restricted in Ethiopia.
Data collection tool, procedure, and quality control
A sample size of 750 individuals were recruited from the
11 enumeration sites (~70 individuals per enumeration
site), and roughly 30 households per enumeration areas
were visited and all adults available in hold holds were
studied. Households were selected using simple random
sampling. Data were collected by trained data collectors
on electronic data collection forms using tools adopted
from similar other studies [11, 18–21]. Open Data Kit
(ODK) was used to collect data electronically. Venous
blood samples were collected by trained laboratory tech-
nicians, nurses, and medical doctors.
Participants were asked history of symptoms within
the last 4 months compatible with COVID-19 (fever,
chills, fatigue, myalgia, sore throat, cough, shortness of
breath, chest pain, headache, nausea, vomiting, head-
ache, and anosmia). They were also asked about contact
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with suspected or confirmed cases and their practice of
COVID-19 prevention measures (i.e., wearing face
masks, social distancing). In this study, proper hand
hygiene practice was defined as a person washes hands;
the front, back, finger tips, rub thumb, and palms with
adequate water and detergent at least for 20–30 s or
uses sanitizer/hand rub to the level of compliance before
getting in the facility or taking the services. Similarly,
proper physical distance was defined as a person keeps 1
m away from another person during getting services,
during greetings, during shopping, during discussing, or
during praying. In addition, mask wearing practice while
leaving home was defined as a person covers the mouth
and nose with mask or any type of cloth or handkerchief
or tissue.
Blood specimen was kept in an extraction tube filled
with extraction buffer (300 μl) at room temperature
(15–30°C) for up to 2 h prior to testing. In addition, re-
frigerator temperature requirement for the SARS-CoV-2
IgG assay was monitored on samples of each day of use
based on the manufacturer’s instruction. Specimen ship-
ment, package, and label were conducted in compliance
with applicable and available national and international
regulations covering the transport of clinical specimens
and infectious substances.
Detection of SARS-CoV-2 IgG antibodies
Serum samples were processed on the Abbott ARCHIT
ECT instrument using the Abbott SARS-CoV-2 IgG
assay following manufacturer’s instructions (SARS-CoV-
2 IgG for use with ARCHITECT; Abbott Laboratories,
Abbott Park, IL, USA) [22]. Although not independently
validated, the Abbott IgG test runs on the ARCHITECT
platform with the approval of the Ethiopian Food and
Drug Administration. The assay is a chemiluminescent
micro-particle immunoassay for qualitative detection of
IgG in human serum or plasma against the SARS-CoV-2
nucleoprotein. The IgG antibodies to SARS-CoV-2 in
each sample were determined by comparing the chemi-
luminescent relative light unit (RLU) in the samples to
the calibrator RLU. Samples were deemed positive if the
index values are above the manufacturer’s recommended
cut off value of 1.40. Using an index signal cut-off (S/C)
threshold of 1.4, the manufacturer reported a sensitivity
of 86.4% after 7 days from symptom onset and 100%
after 14 days, and a specificity of 99.6%, using RT-PCR
as the gold standard. The algorithm has sensitivity of
0 for infections with symptom onset of less than 3
days [11].
Statistical analysis
We estimated seroprevalence as the proportion of
individuals who had a positive result for IgG antibody.
As the study participants did not report COVID-19
symptoms, we did not adjust results for sensitivity of the
test. Estimates of overall prevalence and the 95% confi-
dence interval have been generated using Stata 14 [23].
Similarly, statistical differences in COVID-19 seropreva-
lence between two groups were determined using two
population proportion test. Fisher-exact test was used
for variables with more than two categories. Multilevel
mixed effect binary logistic regression model was fitted
at 95% CI using multiple pridictors including household
clusterring effectson SARS-CoV-2 seroprevalence. Bi-
variate and multivariate multilevel mixed effect logistic
regression analysis was conducted and statistical signifi-
cance was set at p value < 0.05. Variables with a p value
<0.2 in the bivariate analysis were included in the mul-
tiple multilevel mixed effects logistic regression.
Results
Socio demographic characteristics of study participants
Data were analyzed for a total of 684 (91.2%) study
participants after discarding contaminated samples.
Sixty-six (66) samples were not included into this
analysis due to grossly hemolyzed specimens 21
(3.8%), information mismatch on request form 14
(2.1%), insufficient specimen volume 18 (2.7%), and
missing labels on container 13 (2.0%). Although we
designed to exclude individuals with prior history of
RT-PCR test or being positive for RT-PCR test from
the study, none is found with prior history of RT-
PCR test or being positive for RT-PCR test during
the data collection time. The mean age of the study
participants was 37. 6 (SD=15.6 years). Nearly, half
of the participants 362 (52.9%) were in the age
category of 15–34 years and 191 (27.9%) were older
than 45 years (Table 1).
Table 1 Selected socio-demographic characteristics of study
participants for SARS-C-oV-2 seroprevalence, Dire Dawa,
Ethiopia, 2020
Characteristics Category N (%)




Sex (N = 684) Male 307 (44.9)
Female 377 (55.1)
Occupation (N = 684) Employed 370 (54.1)
Jobless 314 (45.9)
Education (N = 682) No formal education 65 (9.5)
Primary education 201 (29.4)
Secondary education 296 (43.3)
Technical or higher education 120 (17.5)
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Behavioral and clinical characteristics
When asked about practicing physical distancing recom-
mendations, more than four fifth 558 (81%) of the re-
spondents did report practicing of physical distancing
recommendations; of which 344 (60%) did often practice
the recommended physical distancing rule (Table 2).
Similarly, from the overall respondents, 583 (85.6%) use
face mask while leaving home, 582 (85.5%) avoid reli-
gious or other social gatherings involving more than four
individuals outside of their households/residence, and
only 119 (17.6%) did report hand washing practice and
use of sanitizers frequently. Concerning main COVID 19
symptoms, all the interviewed respondents did not show
any COVID-19-related symptoms including history of
fever, chills, fatigue, muscle ache (myalgia), sore throat
cough, and known history of contact with anyone with
suspected or confirmed COVID-19 patient from the
time the first COVID-19 case was documented in Dire
Dawa until this survey data was collected.
Seroprevalence of SARS-CoV-2 antibody
During the study period, the prevalence of SARS-CoV-2
IgG antibody was 3.2%, 95% CI 95% CI 2.0–4.8). The
cluster effects is not significant (P = 0.396) suggesting
no evidence of heterogeneity in SARS-CoV-2 seropreva-
lence among the clusters (households). In addition, the
log likelihood was the same for both fixed effects model
and fitted full model. Our prevalence estimates did not
vary by age and sex (Table 3). However, marked differ-
ences were observed in the estimated prevalence by self-
reported practice of the recommended behavioral char-
acteristics. The prevalence of SARS-CoV-2 among par-
ticipants who reported not to have practiced social
distancing was 8.5 times the prevalence in their counter-
parts who reported of practicing social distancing. The
corresponding estimates were 12.8 (95% CI, 7.0, 19) and
was 1.5 (95% CI 0.5, 2.5) with statistically significant dif-
ference (p < 0.01).
Similarly, we observed 4.5 times higher prevalence
among individuals who did not wear facemasks, 10.1%
(95% CI 4.1, 16)) compared to individuals who reported
of wearing them, 2.3% (95% CI 1.0, 4.0) when leaving
home. Participation in social gatherings which involve
more than 4 people is linked to increased prevalence. In
this study, we estimated a prevalence of 10.0% (95% 4.0,
16) among individuals who did not avoid social gather-
ings which is 4.5 times higher compared to prevalence
among individuals who avoided social gathering events.
However, we could not detect a statistically significant
difference in the prevalence of SARS-CoV-2 by hand
washing practice (p = 0.25) (Table 3). With regard to
employment, the prevalence of COVID 19 among indi-
viduals who were employed and work by moving from
home to work area was higher. Individuals who were
employed and commute between work and home had
estimated prevalence of 5.4 (95% CI, 0.03–0.08) com-
pared to individuals who reported no employment 0.1
(95% CI, 0.1–2.1). This observed difference between the
two categories of employment status was statistically
significant (p = 0.001).
Predictors of SARS-CoV-2 antibody seroprevalence
The following explanatory variables with p value less
than 0.20 were selected for multivariate logistic regres-
sion during bivariate analysis of factors associated with
SARS-CoV-2 seroprevalence. These included age, occu-
pation, use of face mask while leaving home, avoiding
religious or other social gatherings, and practicing phys-
ical distancing recommendation measures. From those
five variables entered into the final model, occupation,
use of face mask while leaving home, avoiding religious
or other social gathering events, and practicing physical
distancing recommendation measures showed significant
association with SARS-CoV-2 antibody seroprevalence.
The odds of SARS-CoV-2 antibody seroprevalence was
higher for individuals who were employed and work by
moving from home to work area compared to individ-
uals who reported no employment (AOR; 9.73 95% CI
2.51, 37.68). Similarly, odds of SARS-CoV-2 seropreva-
lence were higher for individuals who did not wear face-
masks compared to individuals who reported of wearing
them when leaving home (AOR; 6.37 95% CI 2.30,
17.66). Likewise, the odds of SARS-CoV-2 antibody
seroprevalence were higher for individuals who did not
practice physical distancing measures compared to indi-
viduals who did practice it (AOR; 10 95% CI 3.00,
33.20). We did not observe significant statistical associ-
ation by age category and by participation status in
social gatherings that involve more than four people
(Table 4).
Discussion
In this survey, the estimated seroprevalence of SARS-
CoV-2 is 3.2% among individuals aged above 15 years in
the study setting. The large proportion of population
(close to 97%) not yet infected at the time of survey
Table 2 Selected clinical and behavioral characteristics of study
participants for SARS-CoV-2 seroprevalence, Dire Dawa, East
Ethiopia, 2020
Behavioral characteristics against COVID-19 Number (%)
Practice physical distancing recommendations (n = 681) 558 (81.9)
Often practice physical distancing recommendations
(n = 558)
344 (60.0)
Wash hand or use sanitizers (n = 677) 120(17.7)
Avoid religious or other social gatherings (n = 681) 582(85.5)
Use face mask while leaving home (n = 681) 583 (85.6)
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meant that promotion of COVID-19 recommended pre-
vention and control measures would be vital to interrupt
the continued community transmission [21].
The prevalence in our study was generally consistent
with other studies conducted during that time when the
epidemic was in its earlier stage. When the study was
undertaken, population level measures that include
school closure, restrictions on social gatherings, and
physical distancing rules were in place in Ethiopia. How-
ever, the estimated SARS-CoV-2 antibody by IgG was
higher compared to studies conducted in Wuhan [19]
and meta-analysis of global pooled seroprevalence [24];
but lower compared to other studies conducted at
Addis Ababa [18], Brazil [20], and Iran [21]. The ob-
served differences might be due to differences in the
stages of the pandemic at the time of the surveys, with
surveys conducted at the earlier stage of the pandemic
more likely to report lower prevalence compared to
those conducted at the later stage. Another main
source of difference is the presence of and level of en-
forcement of population level government restrictions
against COVID-19 to limit transmission.
Table 3 Analysis of SARS-CoV-2 seroprevalence by selected factors among individuals aged above 15 years and residing in
congregate settings of Dire Dawa city administration, Dire Dawa, Ethiopia, 2020
Variables Categories Prevalence (95% CI) P value
Age in years 15–24 5.2 (2.0, 8.0) p = 0.36
25–34 2.2 (0.1, 4.0)
35–44 4.0 (0.6, 7.0)
45–90 2.2 (0.1,4.0)
Sex Male 3.4 (1.0, 5.0) p = 0.96
Female 3.3 (1.0, 5.0)
Employment status Employed 5.4 (3.0, 8.0) p < 0.01
Not employed 0.9 (0.1, 2.0)
Use face cover while leaving home Yes 2.3 (1.0, 4.0) p < 0.001
No 10.1 (4.1, 16)
Avoid going to crowds Yes 2.3 (1.0, 4.0) p < 0.001
No 10.0 (4.0, 16)
Practice physical distancing Yes 1.5 (0.5, 2.5) p < 0.0001
No 12.8 (7, 19)
Frequent hand washing/use of sanitizer Yes 3.0 (2, 4.0) p = 0.25
No 5.1 (1.0, 9.0)
Table 4 Multilevel mixed effects multivariate logistic regression analysis for predictors of SARS-CoV-2 seroprevalence among
individuals aged above 15 years in Dire Dawa, Ethiopia, 2020




25–34 2.45 (0.74,8.09) 0.14 2.1 (0.57,8.2)
35–44 1.04 (0.26, 4.24) 0.95 1.02 (0.22,4.63)
45–90 1.86 (0.49,7.01) 0.37 1.39 (0.31,6.18)
Occupation Employed 5.61 (1.64, 19.14) <0.01 9.73 (2.51, 37.68)*
Jobless 1.00 1.00
Use face mask while leaving home Yes 1.00 1.00
No 4.43 (1.84,10.68) <0.01 6.37 (2.30,17.66)*
Avoid religious or other social gatherings Yes 1.00 1.00
No 4.34 (1.82, 10.54) <0.01 1.02 (0.31, 3.46)
Practice physical distancing recommendations Yes 1.00 1.00
No 9.43 (3.32,26.78) <0.01 10.0 (3.00,33.20)*
1.00: reference. CI confidence interval. COR crude odds ratio. AOR adjusted odds ratio. *P < 0.05
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Consistent with a study from Brazil [20], we could not
detect significant difference in IgG prevalence by sex an
age category. Although such lack of effect of age could
be related to our particular choice of age category, the
differences mean that the risk of getting infection might
not vary by sex and age. The importance of those vari-
ables might be on the progression of and outcome of
disease once infection has occurred.
None of the study participant reported symptoms
compatible with COVID-19 and contact with a known
COVID-19 case. So, the prevalence observed in this
study might be caused predominantly by asymptomatic
community transmission. This underlies the importance
of promoting COVID-19 preventive measures such as
wearing face mask and physical distancing to cut the
asymptomatic transmission in the population. However,
although it may be argued that lack of symptoms com-
patible COVID-19 is partly related to recall bias, the role
of this bias may not be substantial in our study setting.
The main reason is that this study was conducted in a
city administration, where residents have exposure to in-
formation regarding the symptoms and preventive
measures through mainstream media as well local means.
Besides there were strong restrictions imposed at different
stages of the pandemic. These all measures meant that
symptoms are less likely to be forgotten. In addition,
higher self-reported practice of the recommended
COVID-19 prevention measures (more than 80% for most
measures) in our study supports our assertion that the
study population has good awareness of the disease. On
the other hand, study participants might hide their symp-
toms to avoid inpatient admission for at least 14 days.
In this study, the employment status of the participant
was significantly associated with the seroprevalence of
SARS-CoV-2 antibody and significantly higher SARS-
CoV-2 seroprevalence was observed among individuals
who were employed and commute from home to work
and back again compared to those working from home
or jobless and is consistent with other studies [9, 24, 25].
Employments often require frequent movements and
close social interactions and therefore can increase the
risk of asymptomatic transmission of SARS-CoV-2.
In our study, self-reported practice of COVID-19 to
COVID-19 prevention recommendations has roles in the
observed prevalence. In this study, not practicing the
recommended physical distancing measures was signifi-
cantly associated with SARS-CoV-2 seroprevalence. In
particular, we observed 10 times higher prevalence
among individuals who do not practice the recom-
mended physical distancing measures. Our finding repli-
cates findings from a meta-analysis [26]. However, such
effects were not reported in [25, 27, 28] probably related
to the epidemic stage and different state of restrictions
at the time these studies.
Similarly, not frequently using face mask while leaving
homes did show significant association with SARS-CoV-
2 seroprevalence. We also observed, 4.5 times higher
prevalence among respondents not frequently using face
mask while leaving homes compared to those who fre-
quently use it. Consistent with other studies, this study
found higher seroprevalence among those who do not
frequently use face masks [29]. In Ethiopia and in our
study setting, wearing face mask has become mandatory
from the early stages of the epidemic.
Although participating in social gathering events did
not show a significant association with SARS-CoV-2
seroprevalence; the seroprevalence of SARS-CoV-2
among study participants who did not avoid going to
crowds involving more than four people was more than
four times higher compared to those who avoided going
to crowds involving more than four people. This finding
is consistent with a previous study that indicated dispro-
portionately higher prevalence in individuals involved in
crowds [20]. However, we failed to detect significant dif-
ferences in SARS-CoV-2 seroprevalence by hand wash-
ing practice.
Our study has several limitations. The performance of
the test depends on time since infection, with limited
sensitivity for recent infections. At the earlier stage of
the infection, individuals may not yet be able produce
detectable antibodies. As, a result, it is likely that the es-
timated prevalence can be underestimated. Individuals
with mild or asymptomatic infections tend to have lower
IgG responses, so sensitivity of the tests to detect asymp-
tomatic infections is lower, which could lead to under-
estimating seroprevalence. On the other hand, ELISA
tests have shown higher background reactivity in some
sub-Saharan African populations, increasing false posi-
tive rates [30, 31], which is speculated to be connected
to unspecific immune responses from acute malaria.
Therefore, future studies need to look into the validity of
the test results in an Ethiopian setting.
Although it was possible to adjust for such variations
of test performance by time since infection, we could
not adjust our estimates to the sensitivity as none of our
study participants reported symptoms compatible with
COVID-19. Responses regarding COVID-19 recom-
mended preventive measures were subjective self-
reports. It is likely that individuals might not always
maintain the recommended physical distance and proper
mask wearing but can still positively report causing so-
cial desirability bias. Moreover, inclusion of only
crowded neighbourhoods of the city administration in
this survey means that the estimates cannot be represen-
tative for the city administration. Therefore, it is essen-
tial to note that these findings are true for high-density
regions included in this study and should not be general-
ized to the entire city administration.
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Conclusions
In conclusion, the findings of this study imply that
prevalence of COVID-19 was lower, indicating larger
proportion of population was yet to be infected. We also
found that lower seroprevalence among people with self-
reported practice of COVID-19 prevention measures.
Therefore, it is essential to promote and strengthen the
recommended COVID 19 preventive measures to cut
transmissions with in the community.
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